What type of vaccine? Dead virus, attenuated virus, or mRNA?
Yes.
Oxford University launch clinical trial for HIV vaccine
https://www.clinicaltrialsarena.com/news/oxford-uni-hiv-vaccine-trial/...The clinical trial, known as HIV-CORE-0052, will test the HIVconsvX vaccine. This vaccine is a “mosaic” which is capable of targeting a range of HIV-1 variants, opening up the possibility that this single drug could be used across the globe....
...While most HIV vaccine candidates work by inducing antibodies generated by B-cells, HIVconsvX induces the immune system’s potent, pathogen obliterating T cells, targeting them to highly conserved and therefore vulnerable regions of HIV – an “Achilles heel” common to most HIV variants....
Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth
https://pubmed.ncbi.nlm.nih.gov/32640600/...We postulated that focusing a T-cell response on the most vulnerable regions of the HIV-1 proteome while maximizing a perfect match between the vaccine and circulating viruses will control HIV-1 replication. We currently use a combination of replication-deficient simian (chimpanzee) adenovirus and poxvirus modified vaccinia virus Ankara to deliver bivalent conserved-mosaic immunogens to human volunteers. Here, we exploit the mRNA platform by designing tetravalent immunogens designated as HIVconsvM, and demonstrate that mRNA formulated in lipid nanoparticles induces potent, broad and polyfunctional T-cell responses in a pre-clinical model....